Tesamorelin 5mg
Tesamorelin is a stabilized GHRH analog FDA-approved as Egrifta for HIV-associated lipodystrophy. It features a trans-3-hexenoic acid modification that enhances stability. Clinical trials demonstrate significant reduction in visceral adipose tissue, improved lipid profiles, and increased IGF-1 levels.
Sequence
Trans-3-hexenoic acid-GHRH(1-44)-NH2 modified
Market avg: $64.99 — save 38%
Volume pricing
Pay with USDC via Coinbase Commerce
Certificate of Analysis
Independently verified by Janoshik Analytical
Test ID
JAN-TESA-2026-001
Purity
98.8%
Method
HPLC-MS
Batch
TESA-2026-01A
Test Date
February 1, 2026
Identity
Confirmed
Storage Requirements
Lyophilized
2-8°C, protect from light
Reconstituted
2-8°C, use within 14 days
FDA-approved GHRH analog (Egrifta). Refrigerate at all times.
Published Research
2 peer-reviewed studies
Effects of tesamorelin on body composition and metabolic parameters in HIV-infected patients with abdominal fat accumulation
Falutz J, Allas S, Blot K, et al. — Journal of Clinical Endocrinology & Metabolism, 2007
Phase 3 clinical trial demonstrating tesamorelin reduces visceral fat in HIV lipodystrophy.
Tesamorelin for the treatment of HIV-associated lipodystrophy
Stanley TL, Grinspoon SK. — Expert Opinion on Pharmacotherapy, 2012
Comprehensive review of tesamorelin pharmacology and clinical efficacy data.
Related Products
CJC-1295 no DAC 2mg
GHRP-6 5mg
Ipamorelin 5mg
CJC-1295 with DAC 5mg
CJC-1295 + Ipamorelin Blend 10mg
GHRP-2 5mg
Hexarelin 2mg
Sermorelin 5mg
Kisspeptin-10 5mg
Research use only. All products are sold strictly for in-vitro research purposes only. Not for human consumption. Information provided references published research literature. No medical claims are made or implied.